About this Series

Rheumatoid arthritis (RA) treatment has improved dramatically over the past two decades as further insight has been gained into the immune pathophysiology of this chronic joint disease that affects nearly 1.5 million people in the United States.

Biologic therapy, including TNF inhibitors and several non-TNF targeted biologics, has allowed physicians to intervene earlier and enabled patients to achieve quicker relief, more productive lives, and better overall outcomes.

The most recent American College of Rheumatology guidelines for treating RA encourage a collaborative process that considers patients' values, preferences, and comorbidities when choosing therapy. Research suggests that physicians do not always accurately predict their patients' preferences when recommending treatment.

In this series, UCLA rheumatologists and their patients discuss the latest therapies for RA as well as the significance of patient participation in developing effective treatment plans.

Rheumatologists also discuss the importance of patient adherence to therapy, RA remission rates, and why it's often difficult or inappropriate to taper RA patients off of their medication.

Show More

Who's Who
{{#each bp-whos-who.people}}
{{{name}}} {{{addComma prof}}}
{{#if disclosureTitle }} Disclosure
More on Rheumatoid Arthritis